Novartis granted itself a broader pathway into subcutaneous biologic formulations via Alteogen’s ALT-B4 platform. Under option agreements announced after Korean market hours, Alteogen granted Novartis exclusive rights to develop and commercialize multiple products using ALT-B4. The platform approach aims to convert biologic drugs into subcutaneous presentations, potentially widening patient convenience versus intravenous dosing and supporting earlier adoption across therapeutic areas. For Novartis, expanding ALT-B4 coverage strengthens its toolbox for life-cycle management and pipeline packaging. For Alteogen, the exclusivity deal extends the company’s footprint as big pharma continues to seek de-risked formulation routes for next-generation protein therapeutics, particularly as more formats (including multispecifics and ADC-linked proteins) expand the need for workable delivery properties.